StockData
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV (LKFT) company profile

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)

Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –

About Lakefront Biotherapeutics

Pharmaceutical Preparations, SIC 2834

Galapagos NV is a biotechnology enterprise focused on discovering, acquiring, and advancing therapeutics for patients suffering from serious conditions. Operating as a single business segment, the organization concentrates its development pipeline primarily on the therapeutic areas of oncology as well as immunology and inflammation. Following the wind-down of its cell therapy operations, its pipeline centers on clinical-stage investigational assets such as GLPG3667, a selective kinase inhibitor being evaluated for autoimmune disorders. Its intended beneficiaries and end-users are patients facing severe medical diseases.

The company maintains its corporate headquarters and executive offices in Mechelen, Belgium. Historically operating across multiple regions, its ongoing streamlined organization maintains an operational presence and personnel in Mechelen, Chicago, and San Francisco following the closure of facility sites located in the United States, Switzerland, the Netherlands, and China. In addition, its commercial operations previously spanned fourteen European nations prior to business divestment activities.

Summary of the business section of Lakefront Biotherapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Lakefront Biotherapeutics NV
Founded
1999
Headquarters
2800 Mechelen, Belgium
Address
Schalienhoevedreef 20t
Phone
(321) 534-2900
Website
glpg.com
Employees
452, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
C9
Auditor
BDO Bedrijfsrevisoren BV, Zaventem, Belgium

Stock & identifiers

Ticker
LKFT
Other tickers
GLPGF
Former tickers
GLPG until Mar 26, 2026
Exchange
Nasdaq
IPO date
May 14, 2015
Shares outstanding
66M, Dec 31, 2025
Filer category
Large accelerated filer
SEC CIK
1421876
CUSIP
36315X101
ISIN
US36315X1019
FIGI
BBG000BJQY75
Share class FIGI
BBG001SC2MJ9
LEI
549300QKJ78IY0IOV655
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Lakefront Biotherapeutics's leadership is listed in its proxy statement (Form DEF 14A).

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 14, 2015
Exchange
Nasdaq
Lock-up ends (est.)
Nov 10, 2015

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 452 employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 6, 2026Name changeName changed from GALAPAGOS NV to Lakefront Biotherapeutics NV
May 14, 2015IPOInitial public offering priced (424B4 prospectus)
May 8, 2015ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?